EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieStudienprotokollOpen Access

Bladder-Preserving Trimodality Treatment for High-Grade T1 Bladder Cancer: Results From Phase II Protocol NRG Oncology/RTOG 0926

Douglas M Dahl iD, Joseph P Rodgers, William U Shipley iD, M Dror Michaelson iD, Chin-Lee Wu, William Parker, Ashesh B Jani iD, Fabio L Cury iD, Richard S Hudes iD, Jeff M Michalski iD, Alan C Hartford, Daniel Song und 5 weitere

Journal of Clinical Oncology · 2024

DOI: 10.1200/jco.23.02510 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal of Clinical Oncology, 2024. Verfasst von Douglas M Dahl und 16 weiteren Autor:innen. Beteiligte Einrichtung: Massachusetts General Hospital, Harvard Medical School, Boston, MA. Hauptthemen laut MEDLINE: Cystectomy, Urinary Bladder Neoplasms. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE To investigate the use of radiation with radiosensitizing chemotherapy following repeated transurethral resection (trimodality therapy) as an alternative to radical cystectomy in T1 bladder cancer which has failed Bacillus Calmette-Guerin (BCG). PATIENTS AND METHODS Patients with recurrent T1 bladders who had failed BCG and were recommended to undergo cystectomy were treated with trimodality therapy. The primary end point was 3-year freedom from cystectomy. Secondary end points were distant metastasis at 3 and 5 years, local recurrence, disease-specific and overall survival (OS), and safety. RESULTS This single-arm phase II study enrolled 37 patients. Efficacy and safety were evaluated in 34 patients after three exclusions. The median follow-up was 5.1 years. The 3-year freedom from cystectomy rate was 88% (lower one-sided 97.5% confidence limit [CI], 72%), meeting the primary study goal. OS at 3 and 5 years was 69% (95% CI, 54 to 85) and 56% (95% CI, 39 to 74), respectively. The distant metastasis rates at 3 and 5 years were 12% (95% CI, 4 to 26) and 19% (95% CI, 7 to 34), respectively. Eight patients died due to urothelial cancer, 12 exhibited local recurrence at 3 years (cumulative incidence: 32%; 95% CI, 17 to 48), 18 experienced grade 3 adverse events, mostly hematological, and one developed grade 4 neutropenia. CONCLUSION Trimodality therapy is an effective potential alternative to radical cystectomy for recurrent high-grade T1 urothelial cancer of the bladder. At 3 years, 88% of the patients remained free of cystectomy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CystectomyUrinary Bladder NeoplasmsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedAntineoplastic Combined Chemotherapy ProtocolsBCG VaccineCombined Modality TherapyNeoplasm GradingNeoplasm Recurrence, LocalNeoplasm StagingRadiation-Sensitizing Agents

Substanzen

BCG VaccineRadiation-Sensitizing Agents

Autor:innen und Institutionen

  • Massachusetts General Hospital, Harvard Medical School, Boston, MA.
  • NRG Oncology Statistics and Data Management Center, Philadelphia, PA.
  • McGill University Health Centre (MUHC), Montreal, QC.
  • Emory University/Winship Cancer Institute, Atlanta, GA.
  • Saint Agnes Hospital, Baltimore, MD Accruals Under Thomas Jefferson University Hospital, Philadelphia, PA.
  • Washington University School of Medicine, Saint Louis, MO.

ORCID-Profile: Douglas M Dahl, William U Shipley, M Dror Michaelson, Ashesh B Jani, Fabio L Cury, Richard S Hudes, Jeff M Michalski, Deborah E Citrin, Howard M Sandler, Felix Y Feng, Jason A Efstathiou

Förderung

  • NCI NIH HHS

Zitieren

APA

Dahl, D. M., Rodgers, J. P., Shipley, W. U., Michaelson, M. D., Wu, C. L., Parker, W., Jani, A. B., Cury, F. L., Hudes, R. S., Michalski, J. M., Hartford, A. C., Song, D., Citrin, D. E., Karrison, T. G., Sandler, H. M., Feng, F. Y., & Efstathiou, J. A. (2024). Bladder-Preserving Trimodality Treatment for High-Grade T1 Bladder Cancer: Results From Phase II Protocol NRG Oncology/RTOG 0926. Journal of Clinical Oncology. https://doi.org/10.1200/jco.23.02510

Vancouver

Dahl DM, Rodgers JP, Shipley WU, Michaelson MD, Wu CL, Parker W, et al. Bladder-Preserving Trimodality Treatment for High-Grade T1 Bladder Cancer: Results From Phase II Protocol NRG Oncology/RTOG 0926. Journal of Clinical Oncology. 2024. doi:10.1200/jco.23.02510

BibTeX
@article{Dahl2024,
  author = {Dahl, Douglas M and Rodgers, Joseph P and Shipley, William U and Michaelson, M Dror and Wu, Chin-Lee and Parker, William and Jani, Ashesh B and Cury, Fabio L and Hudes, Richard S and Michalski, Jeff M and Hartford, Alan C and Song, Daniel and Citrin, Deborah E and Karrison, Theodore G and Sandler, Howard M and Feng, Felix Y and Efstathiou, Jason A},
  title = {Bladder-Preserving Trimodality Treatment for High-Grade T1 Bladder Cancer: Results From Phase II Protocol NRG Oncology/RTOG 0926},
  journal = {Journal of Clinical Oncology},
  year = {2024},
  doi = {10.1200/jco.23.02510}
}
Kostenlos starten →